Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 401–500 of 1,000
Zhang, N., & Wen, K. (2024) · Oncology Reports · doi:10.3892/or.2024.8801 · Cited by 35
Kim, S., Jeong, H., Ahn, H. K., Han, B., Lee, K.-C., Song, Y. K., Lim, S., Yim, J., Koh, J., & Jeon, Y. K. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013699 · Cited by 35
Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals
Jaffe, E. S. (2019) · Modern Pathology · doi:10.1038/s41379-019-0385-7 · Cited by 35
Self-citationGene expression profiling of primary vitreoretinal lymphoma
Arai, A., Takase, H., Yoshimori, M., Yamamoto, K., Mochizuki, M., & Miura, O. (2020) · Cancer Science · doi:10.1111/cas.14347 · Cited by 35
Lee, M. J., Koff, J. L., Switchenko, J. M., Jhaney, C. I., Harkins, R. A., Patel, S. P., Davé, S. S., & Flowers, C. R. (2020) · Cancer · doi:10.1002/cncr.32866 · Cited by 35
Genetic manipulation and immortalized culture of ex vivo primary human germinal center B cells
Caeser, R., Gao, J., Re, M. D., Gong, C., & Hodson, D. J. (2021) · Nature Protocols · doi:10.1038/s41596-021-00506-4 · Cited by 35
Self-citationNie, M., Du, L., Ren, W., Joung, J., Ye, X., Shi, X., Ciftci, S., Liu, D., Wu, K., Zhang, F., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03695-8 · Cited by 35
Choueiry, F., Singh, S. V., Sircar, A., Laliotis, G., Sun, X., Chavdoula, E., Zhang, S., Helmig-Mason, J., Hart, A., Epperla, N., et al. (2021) · Cancers · doi:10.3390/cancers13092146 · Cited by 35
Chiba, M., Shimono, J., Ishio, T., Takei, N., Kasahara, K., Ogasawara, R., Ara, T., Goto, H., Izumiyama, K., Otsuguro, S., et al. (2022) · Blood · doi:10.1182/blood.2022015646 · Cited by 35
Self-citationBüttner, F., Winter, S., Stühler, V., Rausch, S., Hennenlotter, J., Fuessel, S., Zastrow, S., Meinhardt, M., Toma, M. I., Jerónimo, C., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01105-y · Cited by 35
Activation induced cytidine deaminase: An old friend with new faces
Çakan, E., & Günaydın, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965312 · Cited by 35
Wang, S., Mondal, S., Zhao, C., Berishaj, M., Ghanakota, P., Batlevi, C. L., Doǧan, A., Seshan, V., Abel, R., Green, M. R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127566 · Cited by 35
Lee, J. H., Song, G., Lee, J., Kang, S., Moon, K. M., Choi, Y. D., Shen, J., Noh, M., & Yang, D. (2024) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.12370 · Cited by 35
Choi, J., Ceribelli, M., Phelan, J. D., Häupl, B., Huang, D. W., Wright, G. W., Hsiao, T., Morris, V. M., Ciccarese, F., Wang, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.007 · Cited by 34
Self-citationShao, Y., Lv, X.-Y., Ying, S., & Guo, Q. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2912404 · Cited by 34
Dondolin, R., Garrou, F., Almasri, M., di Bergamo, L. T., Cosentino, C., Bruscaggin, A., Salehi, M., Talotta, D., Bruna, R., Rivolta, G. M., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02688-2 · Cited by 34
Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
Venanzi, A., Marra, A., Schiavoni, G., Milner, S. G., Limongello, R., Santi, A., Pettirossi, V., Ultimo, S., Tasselli, L., Pucciarini, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0203 · Cited by 34
Papageorgiou, S. G., Thomopoulos, T. P., Katagas, I., Bouchla, A., & Pappa, V. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211013987 · Cited by 34
Current progress and future perspectives of research on intravascular large B‐cell lymphoma
Shimada, K., & Kiyoi, H. (2021) · Cancer Science · doi:10.1111/cas.15091 · Cited by 34
de Groen, R. A. L., van Eijk, R., Böehringer, S., van Wezel, T., Raghoo, R., Ruano, D., Jansen, P. M., Bruijn, I. H. B., de Groot, F. A., Kleiverda, K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005215 · Cited by 34
The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
Garcia-Lacarte, M., Grijalba, S. C., Melchor, J., Arnaiz-Leché, A., & Roa, S. (2021) · Cancers · doi:10.3390/cancers13184683 · Cited by 34
Soshnev, A. A., Allis, C. D., Cesarman, E., & Melnick, A. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2619 · Cited by 34
Double-hit lymphoma: optimizing therapy
Dunleavy, K. M. (2021) · Hematology · doi:10.1182/hematology.2021000247 · Cited by 34
BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL
Xia, M., David, L., Teater, M. R., Gutierrez, J., Wang, X., Meydan, C., Lytle, A. G., Slack, G. W., Scott, D. W., Morin, R. D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1566 · Cited by 34
Lou, X., Zhao, K., Xu, J., Shuai, L., Niu, H., Cao, Z., Wang, J., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.950213 · Cited by 34
Self-citationCombining precision oncology and immunotherapy by targeting the MALT1 protease
Mempel, T. R., & Krappmann, D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005442 · Cited by 34
He, Y., Li, J., Ding, N., Wang, X., Deng, L., Xie, Y., Ying, Z., Liu, W., Ping, L., Zhang, C., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1076-4 · Cited by 34
Jiang, P., Yu, F., Zhou, X., Shi, H., He, Q., & Song, X. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012246 · Cited by 33
A decade with whole exome sequencing in haematology
Hansen, M. H., Haferlach, T., & Nyvold, C. G. (2019) · British Journal of Haematology · doi:10.1111/bjh.16249 · Cited by 33
Sewastianik, T., Guerrera, M. L., Adler, K., Dennis, P. S., Wright, K., Shanmugam, V., Huang, Y., Tanton, H., Jiang, M., Kofides, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000588 · Cited by 33
MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome
Qiu, Z., Lin, A., Jiang, S., Elkashef, S. M., Myers, J., Srikantan, S., Sasi, B. K., Cao, J. Z., Godley, L. A., Rakheja, D., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.02.002 · Cited by 33
Lue, J. K., & O’Connor, O. A. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30222-2 · Cited by 33
Chiodin, G., Allen, J. D., Bryant, D. J., Rock, P. J., Martino, E. A., Valle‐Argos, B., Duriez, P. J., Watanabe, Y., Henderson, I., Blachly, J. S., et al. (2021) · Blood · doi:10.1182/blood.2021012052 · Cited by 33
Self-citationH3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients
Schleich, K., Kase, J., Dörr, J. R., Trescher, S., Bhattacharya, A., Yu, Y., Wailes, E. M., Fan, D. N. Y., Lohneis, P., Milanovic, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17467-z · Cited by 32
Molecular classification and therapeutics in diffuse large B-cell lymphoma
Shimkus, G., & NONAKA, T. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1124360 · Cited by 32
Kwok, M., Agathanggelou, A., & Stanković, T. (2024) · Blood · doi:10.1182/blood.2023019963 · Cited by 32
Maher, N., Maiellaro, F., Ghanej, J., Rasi, S., Moia, R., & Gaïdano, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178132 · Cited by 32
Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma
Harkins, R. A., Chang, A., Patel, S. P., Lee, M. J., Goldstein, J., Merdan, S., Flowers, C. R., & Koff, J. L. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1660159 · Cited by 32
Chen, H., Zhang, W., Zhang, L., Yang, P., Li, F., Yang, Z., Wang, J., Pang, M., Hong, Y., Yan, C., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-020-00973-8 · Cited by 32
Self-citationFiskus, W. C., Mill, C. P., Perera, D. N., Birdwell, C. E., Deng, Q., Yang, H., Lara, B. H., Jain, N., Burger, J. A., Ferrajoli, A., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01181-w · Cited by 32
Milpied, P., Gandhi, A. K., Cartron, G., Pasqualucci, L., Tarte, K., Nadel, B., & Roulland, S. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.05.002 · Cited by 32
Self-citationAltered pathways and targeted therapy in double hit lymphoma
Zhuang, Y., Che, J., Wu, M., Guo, Y. L., Xu, Y., Dong, X., & Yang, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01249-9 · Cited by 32
Mangolini, M., Maiqués-Díaz, A., Charalampopoulou, S., Hartmann, E., Bloehdorn, J., Moore, A., Giachetti, G., Lu, J., Franklin, V. N. R., Chilamakuri, C. S. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33739-2 · Cited by 32
Self-citationTowards precision medicine in lymphoid malignancies
Bühler, M. M., Martín-Subero, J. I., Pan‐Hammarström, Q., Campo, E., & Rosenquist, R. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13423 · Cited by 32
Self-citationTaming the Heterogeneity of Aggressive Lymphomas for Precision Therapy
Young, R. M., Phelan, J. D., Shaffer, A. L., Wright, G. W., Huang, D. W., Schmitz, R., Johnson, C. A., Oellerich, T., Wilson, W. H., & Staudt, L. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055734 · Cited by 31
Self-citationEμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Lucas, F. M., Rogers, K. A., Harrington, B. K., Pan, A., Yu, L., Breitbach, J. T., Bundschuh, R. A., Goettl, V. M., Hing, Z. A., Kanga, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0273 · Cited by 31
Drug therapy for double-hit lymphoma
Phuoc, V. H., Sandoval-Sus, J. D., & Chávez, J. C. (2019) · Drugs in Context · doi:10.7573/dic.2019-8-1 · Cited by 31
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Lee, B., Lee, H., Cho, J., Yoon, S. E., Kim, S. J., Park, W., Kim, W. S., & Ko, Y. H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628807 · Cited by 31
New developments in non-Hodgkin lymphoid malignancies
Ganapathi, K. A., Brown, L. E., Prakash, S., & Bhargava, P. (2021) · Pathology · doi:10.1016/j.pathol.2021.01.002 · Cited by 31
Regnase-1 is essential for B cell homeostasis to prevent immunopathology
Bhat, N., Virgen‐Slane, R., Ramezani-Rad, P., Leung, C. R., Chen, C., Balsells, D., Shukla, A., Kao, E., Apgar, J. R., Fu, M., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200971 · Cited by 31
Jiang, D., Mo, Q., Sun, X., Wang, X., Dong, M., Zhang, G., Chen, F., & Zhao, Q. (2021) · Cancer Science · doi:10.1111/cas.15055 · Cited by 31
Croci, G. A., Au-Yeung, R. K. H., Reinke, S., Staiger, A. M., Koch, K., Oschlies, I., Richter, J., Poeschel, V., Held, G., Loeffler, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1991 · Cited by 31
Self-citationNF-κB: a mediator that promotes or inhibits angiogenesis in human diseases?
Jiang, Y., Zhang, J., Shi, C., Li, X., Jiang, Y., & Mao, R. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.20 · Cited by 31
Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review
Arzuaga‐Méndez, J., Prieto‐Fernández, E., López-López, E., Martín‐Guerrero, I., García‐Ruiz, J. C., & García‐Orad, Á. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.013 · Cited by 31
Krull, J. E., Wenzl, K., Hartert, K. T., Manske, M. K., Sarangi, V., Maurer, M. J., Larson, M. C., Nowakowski, G. S., Ansell, S. M., McPhail, E. D., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00382-3 · Cited by 31
Peeters, J. G. C., Silveria, S. L., Özdemir, M., Ramachandran, S., & DuPage, M. J. P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114724 · Cited by 30
Cassim, S., Antel, K. R., Chetty, D. R., Oosthuizen, J., Opie, J., Mohamed, Z., & Verburgh, E. R. (2020) · Pathology · doi:10.1016/j.pathol.2020.02.007 · Cited by 30
An Epigenetic Mechanism Underlying Chromosome 17p Deletion–Driven Tumorigenesis
Chen, M., Chen, X., Li, S., Pan, X., Gong, Y., Zheng, J., Xu, J., Zhao, C., Zhang, Q., Zhang, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0336 · Cited by 30
Ofori, K., Bhagat, G., & Rai, A. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14611 · Cited by 30
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 31
Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma
Donati, G., Ravà, M., Filipuzzi, M., Nicoli, P., Cassina, L., Verrecchia, A., Doni, M., Rodighiero, S., Parodi, F., Boletta, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13115 · Cited by 30
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma
Li, P., Chai, J., Chen, Z., Liu, Y., Wei, J., Liu, Y., Zhao, D., Ma, J., Wang, K., Li, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.622648 · Cited by 30
Wang, X., Hong, Y., Meng, S., Gong, W., Ren, T., Zhang, T., Liu, X., Li, L., Qiu, L., Qian, Z., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109105 · Cited by 30
Self-citationTherapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
Effer, B. R., Perez, I., Ulloa, D., Mayer, C., Muñoz, F., Bustos, D., Rojas, C., Manterola, C., Vergara-Gómez, L., Dappolonnio, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11072086 · Cited by 30
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas
D’Alò, F., Bellesi, S., Maiolo, E., Alma, E., Bellisario, F., Malafronte, R., Viscovo, M., Campana, F., & Hohaus, S. (2024) · Cancers · doi:10.3390/cancers16122243 · Cited by 30
Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq
Giannuzzi, D., Marconato, L., Cascione, L., Comazzi, S., Elgendy, R., Pegolo, S., Cecchinato, A., Bertoni, F., Aresu, L., & Ferraresso, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215154 · Cited by 30
Tanaka, Y., Momose, S., Tabayashi, T., Sawada, K., Yamashita, T., Higashi, M., Sagawa, M., Tokuhira, M., Rosenwald, A., Kizaki, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14286 · Cited by 30
Self-citationHu, L., Zhao, J., Liu, Y., Liu, X. Z., Lu, Q., Zeng, Z. R., Zhu, L., Tong, X., & Xu, Q. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.51329 · Cited by 30
Self-citationGhafouri, S. N., Fenerty, K. E., Schiller, G. J., de Vos, S., Eradat, H. A., Timmerman, J. M., Larson, S. M., & Mead, M. D. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.002 · Cited by 30
Yang, Y., Bolomsky, A., Oellerich, T., Chen, P., Ceribelli, M., Häupl, B., Wright, G. W., Phelan, J. D., Huang, D. W., Lord, J. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33142-x · Cited by 29
“Sequencing and analysis to obtain digital gene expression were previously described (62).”
BackgroundMethodInfluentialSelf-citationIQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL
Tang, T., Wang, J., Zhang, L., Cheng, Y., Saleh, L., Gu, Y., & Zhang, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08086-y · Cited by 29
Self-citationNew Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?
Abrisqueta, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071929 · Cited by 29
Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1732079 · Cited by 29
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences
Carrassa, L., Colombo, I., Damia, G. L. M., & Bertoni, F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102090 · Cited by 29
Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm
Crombie, J. L., & Armand, P. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01501 · Cited by 29
Ma, J., Yan, Z., Zhang, J., Zhou, W., Yao, Z., Wang, H., Chu, J., Yao, S., Zhao, S., Zhang, P., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-00214-3 · Cited by 29
Zucca, E., Cascione, L., Ruberto, T., Facchinelli, D., Schär, S., Hayoz, S., Dirnhofer, S., Giovanella, L., Bargetzi, M. J., Mamot, C., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2805 · Cited by 29
Vajavaara, H., Mortensen, J. B., Leivonen, S., Hansen, I. M., Ludvigsen, M., Holte, H., Jørgensen, J. M., Bjerre, M., d’Amore, F., & Leppä, S. (2021) · Cancers · doi:10.3390/cancers13030398 · Cited by 29
Refractory DLBCL: Challenges and Treatment
Goldfinger, M., & COOPER, D. L. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.011 · Cited by 29
Bertram, K., Leary, P., Boudesco, C., Fullin, J., Stirm, K., Dalal, V., Zenz, T., Tzankov, A., & Mueller, A. (2021) · Leukemia · doi:10.1038/s41375-021-01470-4 · Cited by 29
The metabolic plasticity of B cells
Vivas, Y., & Efeyan, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.991188 · Cited by 29
NF-κB Mutations in Germinal Center B-Cell Lymphomas: Relation to NF-κB Function in Normal B Cells
Pasqualucci, L., & Klein, U. (2022) · Biomedicines · doi:10.3390/biomedicines10102450 · Cited by 29
Li, S.-S., Zhai, X., Liu, H., Liu, T., Cao, T., Chen, D., Xiao, L.-X., Gan, X., Cheng, K., Hong, W.-J., et al. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00325-7 · Cited by 29
DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance
Zhou, N., Choi, J., Grothusen, G. P., Kim, B., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A. A., Beer, T., et al. (2023) · Blood · doi:10.1182/blood.2022018752 · Cited by 29
Roschewski, M. J., Patel, M. R., Reagan, P. M., Saba, N. S., Collins, G. P., Arkenau, H., de Vos, S., Nuttall, B. R. B., Acar, M., Burke, K. A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2483 · Cited by 29
Moia, R., Talotta, D., di Bergamo, L. T., Almasri, M., Dondolin, R., Salehi, M., Cosentino, C., Soscia, R., Starza, I. D., Bruscaggin, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014136 · Cited by 29
Role of Specific B-Cell Receptor Antigens in Lymphomagenesis
Thurner, L., Hartmann, S., Neumann, F., Hoth, M., Stilgenbauer, S., Küppers, R., Preuss, K., & Bewarder, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.604685 · Cited by 29
The high-grade B-cell lymphomas: double hit and more
Davies, A. J. (2024) · Blood · doi:10.1182/blood.2023020780 · Cited by 28
Kaulen, L. D., Martinez‐Lage, M., Abramson, J. S., Karschnia, P., Doubrovinskaia, S., Shankar, G. M., Choi, B. D., Ramundo, C. M., Ehret, F., Barnes, J. A., et al. (2025) · Blood · doi:10.1182/blood.2025028964 · Cited by 28
Yan, W., Jiang, X., Wang, W., Sun, Y.-F., Wo, Y., Luo, Z.-Z., Xu, Q., Zhou, X., Cao, J., Hong, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00803 · Cited by 28
A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma
Zhou, H., Zheng, C. J., & Huang, D. (2020) · PeerJ · doi:10.7717/peerj.9658 · Cited by 28
Self-citationRaman, L., Linden, M. V. D., Vriendt, C. D., den Broeck, B. V., Muylle, K., Deeren, D., Dedeurwaerdere, F., Verbeke, S., Dendooven, A., Grove, K. C. D., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.268813 · Cited by 28
Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma
Léveillé, E., & Johnson, N. A. (2021) · Cancers · doi:10.3390/cancers13092167 · Cited by 28
CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights
Ali, A., Goy, A. H., & Dunleavy, K. M. (2022) · Blood · doi:10.1182/blood.2022016226 · Cited by 28
Ritter, Z., Papp, L., Zámbó, K., Toth, Z. G., Dezső, D., Veres, D. S., Máthé, D., Budán, F., Karádi, É., Balikó, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.820136 · Cited by 28
Extracellular Vesicles in Diffuse Large B Cell Lymphoma: Characterization and Diagnostic Potential
Matthiesen, R., Gameiro, P., Henriques, A. F. A., Bodo, C., Moraes, M. C. S., Costa‐Silva, B., Cabeçadas, J., da Silva, M. G., Beck, H. C., & Carvalho, A. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113327 · Cited by 28
Solsona, B. G., Horn, H., Schmitt, A., Xu, W., Bucher, P., Heinrich, A., Kalmbach, S., Kreienkamp, N., Franke, M., Wimmers, F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010964 · Cited by 28
Self-citationBiological signatures of the International Prognostic Index in diffuse large B-cell lymphoma
Wang, Y., Shi, Q., Shi, Z., Tian, S., Zhang, M., Shen, R., Fu, D., Dong, L., Yi, H., Ouyang, B., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011425 · Cited by 29
Ben-Barouch, S., & Kuruvilla, J. G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1706087 · Cited by 28
Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis
Sommermann, T. G., Yasuda, T., Ronen, J., Wirtz, T., Weber, T., Sack, U., Caeser, R., Zhang, J., Li, X., Chu, V. T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921139117 · Cited by 28
Self-citation
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.